Cold Pain Therapy Market Analyzed Globally by Top Key Players, Trends, Share, Growth Rate and Forecast

According to the new market research report "Cold Pain Therapy Market by Product (OTC (Gels, Creams, Patches, Wraps, Pads), Prescription (Motorized, Non-motorized)), Application (Musculoskeletal, Post-Op, Sports Injuries), Distribution Channel (Hospital, Retail, E-Pharmacy) - Global Forecast to 2027", published by MarketsandMarkets™, the Cold Pain Therapy Market was valued at USD 1.8 billion in 2022 and is projected to reach USD 2.4 billion by 2027 growing at a CAGR of 5.1%.

Browse in-depth TOC on "Cold Pain Therapy Market"
243 – Tables
42 – Figures
249 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=55543905

The rising awareness about the cost-effective cold pain relief products, and rising prevalence of arthritis. Emerging economies such as China, Japan, and India are providing profitable opportunities for the players operating in the market.

The OTC products segment accounted for the largest share of the cold pain therapy market, by product segment, in 2021

The market is segmented into OTC products and prescription products. The OTC products holds the largest share of the market in 2021, mainly due to the presence of substantial clinical evidence in favor of cooling gels as sports medicine.

Musculoskeletal disorders segment to register the highest growth rate during the forecast period

The cold pain therapy market has been segmented into musculoskeletal disorders, sports medicine, post-operative therapy, and post-trauma therapy. In 2021, the musculoskeletal disorders segment accounted for the largest share of the market. Factors such as rising geriatric population due to which there is higher prevalence of musculoskeletal disorders and increasing self-care awareness will drive the growth of this segment.

The retail pharmacies segment accounted for the largest share of the cold pain therapy, by distribution channel segment, in 2021

Based on the distribution channel, the cold pain therapy market has been segmented into hospital pharmacies, retail pharmacies, and e-pharmacies. In 2021, the retail pharmacies segment accounted for the largest share of the market. The implementation of government regulations for proper functioning of retail pharmacies is driving the growth of this segment.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=55543905

North America is the largest regional market for cold pain therapy market

The global cold pain therapy market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America accounted for the largest share of the market. The North American market growth can be attributed to the growing incidence of arthritis.

The major players operating in this cold pain therapy market are Beiersdorf AG (Germany), DJO Global, Inc. (US), Hisamitsu Pharmaceutical Co., Inc. (Japan), Össur (Iceland), Johnson & Johnson (US), Pfizer (US), Sanofi (France), Rohto Pharmaceutical (Japan), 3M (US), Cardinal Health Inc. (US), Bird & Cronin (US), Compass Health Brands (US), Breg, Inc. (US), Medline Industries (US), Performance Health (US), Romsons Group of Industries (India), Unexo Life Sciences (India), Polar Products (US), Rapid Aid (Canada), Mueller Sports Medicine (US), Pic Solution (US), Bruder Healthcare Company (US), Brownmed Inc. (US), Medichill (Australia), and ThermoTek, Inc. (US).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=55543905

Point of Care Diagnostics Market - Insights and In Depth Analysis of Industry Segments and Key Players

Growth Factors Driving the Market: The Point of Care Diagnostics Market growth is mainly driven by the high prevalence of infectious diseases, supportive government policies and rising number of CLIA-waived POC tests. In addition, healthcare decentralization and greater investments and funding for product development are expected to offer growth opportunities for players in the point of care diagnostics market. However, issues related to pricing pressure owing to reimbursement cuts and budget constraints are expected to hinder the growth of the point of care diagnostics market during the forecast period.

MarketsandMarkets™ View on Revenue: The global point of care and rapid diagnostics market is expected to reach USD 72.0 billion by 2027 from an estimated USD 43.2 billion in 2022, at a CAGR of 10.8% from 2022 to 2027.

Industry Segmentation in Detailed:

The Glucose Monitoring Products segment accounted for the largest share of the point of care diagnostics market.

Based on products, the point-of-care diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, COVID-19 testing products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, hematology testing products, tumor/cancer marker testing products, fecal occult testing products, urinalysis testing products, drug-of-abuse testing products, cholesterol testing products, and other products. In 2021, the glucose monitoring products segment accounted for the largest share of the point-of-care diagnostics market. This can be attributed to the growing diabetic patient population base, ongoing technological advancements, and the growing preference for home glucose testing.

The Lateral Flow Assays segment accounted for the largest share of the poc diagnostics market.

Based on platform, the point-of-care diagnostics market is segmented into lateral flow assays, immunoassays, microfluidics, dipsticks, and molecular diagnostics. The lateral flow assays segment accounted for the largest share of the market in 2021. The widespread adoption of lateral flow assays in POC testing as a replacement for lengthy, conventional laboratory procedures is a key factor contributing to the growth of this segment.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=106829185

Leading Key Players Analysis:

Prominent players in the point-of-care diagnostics market include Abbott Laboratories (US), Siemens Healthineers AG (Germany), Quidel Corporation (US), F. Hoffman-La Roche Ltd. (Switzerland), Danaher Corporation (US), Becton, Dickinson and Company (US), Chembio Diagnostics (US), EKF Diagnostics (UK), Trinity Biotech plc (Ireland), Instrumentation Laboratory (a Werfen Company) (US), Nova Biomedical (US), PTS Diagnostics (US), Sekisui Diagnostics (US), Thermo Fisher Scientific (US), and bioMérieux S.A. (France)

Geographical Trends in Detailed:

The global point of care diagnostics market is segmented into North America (comprising the US and Canada), Europe (includes Germany, France, and the UK), the Asia Pacific (includes Japan, China, India), Latin America (Brazil, Mexico), and the Middle East & Africa. In 2021, North America accounted for the largest share of this market, followed by Europe. The rising prevalence of lifestyle diseases, growing number of product approvals, and government initiatives to support the wider adoption of POC testing products are the key factors driving the growth of the North American point-of-care diagnostics market.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=106829185

Global Lateral Flow Assays Market Competitive Landscape, and CAGR Status

Growth Factors Driving the Market: The high prevalence of infectious diseases worldwide, rapid growth in the geriatric population, growing demand for point-of-care testing, and rising use of home-based lateral flow assay devices are the major factors driving the growth of this market. On the other hand, reluctance among doctors and patients to change existing diagnostic procedures and the low accuracy of lateral flow assays are the key restraints.

The high prevalence of infectious diseases, such as HIV and malaria, coupled with the underdeveloped healthcare infrastructural facilities and increasing public awareness in developing countries, is expected to drive the adoption of lateral flow assay tests in these countries. In addition, recent outbreaks of infectious diseases from the spread of viruses (such as Ebola, H1N1, and Zika) have highlighted the need for early disease detection capabilities, which is also expected to drive market growth. The current COVID-19 pandemic has resulted in high demand for rapid diagnostic testing through lateral flow technology, supporting the growth of this market in the coming year.

MarketsandMarkets™ View on Revenue: The global lateral flow assays market is projected to reach USD 12.6 billion by 2026, at a CAGR of 2.0% during the forecast period.

Industry Segmentation in Detailed:

The Rising demand for lateral flow assays in the food & beverage industry;

Food safety issues and concerns for public health have led to the implementation of more stringent legislation for food safety in several countries. This resulted in an increased demand for pathogen and toxin tests in just about every segment of the food production industry—processed foods, meats, poultry, beverages, and dairy—and among all major food producers worldwide.

Earlier, most food safety tests were performed using lab-based traditional microbiology techniques, but rapid, on-the-spot tests have seen growing use in this area. These tests are used primarily for testing raw materials, interim products in the manufacturing process, and final products for bacteria such as Listeria, Salmonella, and E. coli. In August 2020, PerkinElmer launched a COVID-19 environmental surface testing kit to detect the virus in food processors. Furthermore, the food industry has also shown a demand for tests capable of detecting mycotoxins and allergens—such as RIDA QUICK rapid tests from R-Biopharm. Merck KGaA (Germany) provides Singlepath L’mono for detecting Listeria monocytogenes; Singlepath Salmonella for salmonella, and Singlepath Campylobacter for Campylobacter in foods.

“Kits & Reagents segment accounted for the largest share in the lateral flow assays market.”

The lateral flow assays market is segmented into kits & reagents and lateral flow readers. In 2020, kits & reagents accounted for the larger share of the global lateral flow assays market. The large share of this segment can be attributed to the increasing application of lateral flow kits & reagents for POC testing, during the forecast period.

 

 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167205133

Leading Key Players Analysis:

The prominent players in the global lateral flow assays market include Abbott Laboratories (US), Quidel Corporation (US), F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), Siemens AG (Germany), BD (US), bioMérieux SA (France), Bio-Rad Laboratories (US), Thermo Fisher Scientific, Inc. (US), PerkinElmer Inc. (US), Hologic Inc. (US), QIAGEN N.V. (Netherlands), and Merck KGaA (Germany).

Geographical Trends in Detailed:

The North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the lateral flow assays market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. However, the APAC is expected to grow at the highest CAGR during the forecast period. The rapidly developing healthcare industry in China and India, growth in the aging population reasons for high growth rate in the lateral flow assays market in this region.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=167205133

Breast Reconstruction Market - Growth and key Industry Players Analysis 2021 and Forecast

Growth Factors Driving the Market: The emergence of 3D-printed implants can provide significant opportunities for market growth. German companies, BellaSeno and Evonik, have entered into a collaboration to develop 3D breast implant technology. BellaSeno will use Evonik’s Resomer bioresorbable polymer in its Senella breast scaffolds, avoiding the use of silicone implants that have raised major safety concerns.

BellaSeno planned to start the first human clinical trials of the Senella scaffolds with Resomer in Germany in 2019. Evonik has supplied its Resomer polymer for clinical and commercial use. The scaffolds are designed to guide the growth of the natural tissue using the patient's body fat harvested via liposuction. This product is designed to be used after augmentation, reconstruction, and revision surgery. This is progressively reabsorbed by the body and replaced with natural breast tissue. This technology avoids the use of silicone implants and their associated complications & risk, like capsular contracture, rupture, and deflation. Moreover, in December 2021, Bellaseno GmbH reported the publication of first-in-human data for its 3D-printed biodegradable and highly porous Senella scaffold filled with an autologous fat graft to correct a chest deformation in a 22-year-old patient with severe pectus excavatum. The article was published in the European Journal of Plastic Surgery.

MarketsandMarkets™ View on Revenue: The global breast reconstruction market size is expected to grow from USD 647 million by 2026 to USD 567 million in 2021, at a CAGR of 2.7%.

Industry Segmentation in Detailed:

"Breast implants accounted for the largest share of the breast reconstruction market"

Based on the product, the breast reconstruction market is segmented into breast implants, tissue expanders, and acellular dermal matrix. The breast implants segment accounted for the largest market share in 2020.

"The immediate procedures segment accounted for the largest market share in 2020."

Based on the procedure, the breast reconstruction market is segmented into immediate, delayed, and revision procedures. The immediate procedures segment accounted for the largest market share in 2020. This is primarily attributed to the increasing number of surgeries post-mastectomy and rising awareness.

"The unilateral segment accounted for the largest market share in 2020."

Based on type, the breast reconstruction market is segmented into unilateral and bilateral. The unilateral segment accounted for the largest market share in 2020. The increasing incidence of breast cancer and rising awareness are major factors responsible for the dominant share of this segment.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186501593

Leading Key Players Analysis:

The prominent players operating in this market include Mentor Worldwide LLC (Johnson & Johnson) (US), are Allergan Aesthetics (an Abbvie company) (US), Ideal Implant Incorporated (US), Sebbin (France), GC Aesthetics (Ireland), POLYTECH Health & Aesthetics (Germany), Sientra (US), Integra Lifesciences (US), RTI Surgical Holdings (US), Establishment Labs S.A. (US), Silimed (Brazil), Laboratories Arion (France), and other players are Guangzhou Wanhe Plastic Materials Co. Ltd.(China), CEREPLAS (France), HansBiomed (South Korea), PMT Corporation (US), and Shanghai Kangning Medical Device (China)

Mentor Worldwide LLC (Johnson & Johnson) (US) is one of the leading players in the breast reconstruction market. The company offers a broad product portfolio across the globe. Over the years, the company has maintained its leading position in the breast reconstruction market.

Geographical Trends in Detailed:

North America was the largest regional market for breast reconstruction in 2020;

The breast reconstruction market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2020, North America held the largest share of the market, followed by Europe. The rising incidences of breast cancer, increasing awareness of breast reconstruction, and FDA approvals for breast reconstruction products in this region are the major factors driving the growth of the breast reconstruction in North America.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=186501593

In-depth Analysis of the COVID-19 Impact on Global In Vivo Toxicology Market 2022

Growth Factors Driving the Market: The In Vivo Toxicology Market growth is driven largely by the increasing pharmaceutical R&D activities, innovations in animal models, the development of exclusive in vivo toxicology tests, and the increasing demand for personalized medicine

MarketsandMarkets™ View on Revenue: The global in vivo toxicology market size is projected to reach USD 6.6 billion by 2025 from USD 5.0 billion in 2020, at a CAGR of 5.5% during the forecast period.

Industry Segmentation in Detailed:

The immunotoxicity segment accounted for the largest share of the in vivo toxicology market.

Based on toxicity endpoint, the global in vivo toxicology market is segmented into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental & reproductive toxicity (DART), and other toxicity endpoints (includes organ toxicity, endocrine disruptor toxicity, juvenile toxicity, phototoxicity, ocular toxicity, and skin irritation). In 2019, the immunotoxicity segment accounted for the largest share of the global in vivo toxicology market, followed by the systemic toxicity segment.The rising demand for the development of biologics and biosimilars is driving the growth of the immunotoxicity segment

The chronic test type segment accounted for the largest share of the in vivo toxicology market.

Based on test type, the global in vivo toxicology testing market is segmented into acute, sub-acute, sub-chronic, and chronic test type. The chronic test type segment is expected to dominate the market during the forecast period. In 2019, the chronic test type segment held the largest share of the market, followed by sub-chronic test type.Increasing research on drugs used for longer-duration therapy such as anti-cancer, anti-convulsive, anti-arthritis, and anti-hypertensives drives the growth of the chronic test type market.

The outsourced testing facilities segment accounted for the largest share of the in vivo toxicology market.

Based on the testing facility, the global in vivo toxicology market is segmented into outsourced testing facilities and in-house testing facilities. The outsourced testing facilities segment is expected to dominate the market, by testing facility, over the forecast period. In 2019, the outsourced testing facilities segment held the largest share of the global in vivo toxicology market. The large share of this segment is attributed to the increasing R&D investments and cost-saving strategies of pharmaceutical, biopharmaceutical, and medical devices companies, resulting in increased outsourcing of services to CROs

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=105308811

Leading Key Players Analysis:

The major players operating in In Vivo Toxicology Testing Market are by Charles River Laboratories (US), The Jackson Laboratory (US), Envigo (US), Taconic Biosciences, Inc. (US), and JANVIER LABS (France), Thermo Fisher Scientific (US), Danaher Corporation (US), Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Bruker Corporation (US), PerkinElmer (US). Other prominent players include Merck KGaA (Germany), GE Healthcare (US), and Bio-Rad Laboratories (US), genOway (France), Cyagen Biosciences (US), GVK BIO (India), PolyGene (Switzerland), Crown Biosciences (US), TransCure bioServices (France), Ozgene Pty Ltd. (Australia), Harbour BioMed (US) among others.

 

Geographical Trends in Detailed:

The global in vivo toxicology market is segmented into North America, Europe, the Asia Pacific, Latin Ametica and Middle East & Africa. In 2019, North America accounted for the largest share of the in vivo toxicology market. The large share of the North America region can be attributed to the presence of major players operating in the in vivo toxicology market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.

 

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=105308811

Contract Research Organization Services Market - Emerging Industry Trends and Global Future Forecast

Growth Factors Driving the Market: The Growth in CRO services market can mainly be attributed to factors such as the increasing investment in pharmaceutical R&D, rising number of clinical trials, high cost of in-house drug development (encouraging pharma-biotech companies to opt for outsourcing), and the rising prevalence of orphan and rare diseases (creating new revenue pockets for CROs). Growth in the drugs and biologics market despite the COVID-19 pandemic, the increasing demand for specialized testing services among end users, and the need for novel clinical trial designs for complex cell and gene therapies are also expected to offer a wide range of growth opportunities to players operating in this market.

MarketsandMarkets™ View on Revenue: The Global Contract Research Organization (CROs) Services Market is estimated to grow from USD 115.1 billion by 2027 from USD 68.3 billion in 2022, at a CAGR of 11.0% during the forecast period.

Industry Segmentation in Detailed:

The clinical research services subsegment accounted for the largest share of the type segment in the CRO services market in 2021.

Based on type, the CRO services market is segmented into clinical research services, early-phase development services, laboratory services, consulting services, and data management services. The clinical research services segment accounted for the largest share of this market in 2021. The large share of this segment can primarily be attributed to factors such as the increasing R&D of new drugs and the high cost of clinical trials.

The oncology subsegment accounted for the largest share of the therapeutic area segment in the CRO services market in 2021.

Based on therapeutic area, the CRO services market is segmented into oncology, infectious diseases, neurology, vaccines, cardiovascular system (CVS) disorders, metabolic disorders/endocrinology, immunological disorders, respiratory disorders, psychiatry, dermatology, hematology, ophthalmology, gastrointestinal diseases, genitourinary & women’s health, and other therapeutic areas. The oncology segment accounted for the largest share of the global CRO services market in 2021. The large share of this segment is primarily attributed to the increasing number of drug discovery activities for oncology and the rising prevalence of cancer worldwide.

 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167410116

Leading Key Players Analysis:

The Asia Pacific region is the fastest-growing region of the CRO services market.

 

Key players in the global CRO servicesMarket include IQVIA Inc. (US), Laboratory Corporation of America Holdings (US), PPD, Inc. (a part of Thermo Fisher Scientific, Inc.), ICON plc (Ireland), Charles River Laboratories International, Inc. (US), WuXiAppTec Co., Ltd. (China), Syneos Health Inc. (US), Parexel International Corporation (US).

 

Geographical Trends in Detailed:

The global CRO services market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The market in the Asia Pacific is estimated to record the highest CAGR during the forecast period. This can be attributed to the fast-growing pharmaceutical industry in the region, favorable government policies, increasing number of pharmaceutical companies establishing their manufacturing facilities in the region, and the lower cost of clinical trials in the region.

 

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=167410116

Cancer Diagnostics Market - Growth and key Players Analysis and Forecast

Growth Factors Driving the Market:  The Growth of the Cancer Diagnostics Market is driven mainly by increasing incidence of cancer and growth in the number of private diagnostic laboratories.

In an attempt to detect cancer in the early stages and bring down the mortality rate, governments in developed countries and primary care doctors are recommending cancer screening tests for patients. The US Preventive Services Task Force (USPSTF) recommends screening for colorectal cancer starting at 50 years of age to 75 years of age in the US as a means of preventing disease incidence and ensuring early-stage treatment. Canada has also implemented guidelines for biennial colorectal cancer screening for people aged 50 to 74 years.

MarketsandMarkets™ View on Revenue: The global cancer diagnostics market size was valued at USD 17.2 billion in 2021 and is expected to grow at a CAGR of 11.5%

Industry Segmentation in Detailed:

The consumables segment is expected to grow at the highest CAGR during the forecast period.

Based on the product, the cancer diagnostics market is segmented into consumables and instruments. The consumables segment is projected to witness the highest growth during the forecast period. The repeated purchase and high consumption, and the high prevalence of diseases the major factors supporting the growth of this segment.

The technology segment accounted for the largest share of the cancer diagnostics market.

By technology, the cancer diagnostics market is segmented IVD testing, imaging based and biopsy technique. The IVD testing segment accounted for the largest market share in 2020. The large share of this segment can be attributed to increasing incidence of cancer.

Hospitals for the largest share of the cancer diagnostics market.

Based on end-users, the cancer diagnostics market is segmented into hospitals and diagnostic laboratories. The hospitals segment accounted for the largest share of the cancer diagnostics market in 2020. The increasing number of patients visiting hospitals, rising number of in-house diagnostic procedures performed in hospitals, and growing awareness regarding early diagnosis is are the major driving factor for this market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186559121

Leading Key Players Analysis:

Some of the major players operating in this market are GE Healthcare (US), Roche Diagnostics (Switzerland), and Becton, Dickinson and Company (US). In 2020, GE Healthcare held the leading position in the market. The company has a strong geographic presence across the US, Asia, Europe, Middle East and Africa, & the Americas. Moreover, the company’s strong brand recognition and comprehensive product portfolio in the cancer diagnostics market is its key strength. BD held the second position in the cancer diagnostics market in 2020.

Geographical Trends in Detailed:

The cancer diagnostics market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World. In 2020, North America accounted for the largest share of the cancer diagnostics market. The large share of North America can be attributed to factors such as the increasing incidences of cancer, growing awareness early diagnosis and technological advancement.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=186559121

Aptamers Market - Developing Regions is Well-Positioned for Strong Growth in the Coming Years

Growth Factors Driving the Market: The Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical R&D, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics. Growth in the venture capital funding for research on aptamers and growing collaborations with research institutes and pharmaceutical companies are also expected to offer a wide range of growth opportunities to players in the market. On the other hand, low market acceptance as compared to antibodies is likely to restrain the market growth while shortage of skilled & trained professionals may challenge market growth to a certain extent.

MarketsandMarkets™ View on Revenue: The aptamers market valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period.

Industry Segmentation in Detailed:

“The therapeutics development segment will continue to dominate the aptamers application market during the forecast period”

Based on the application, the aptamers market is segmented into therapeutics development, research & development, diagnostics, and other applications. In 2020, the therapeutics development segment dominated the market due to the increasing number of clinical trials evaluating aptamers for new therapies and collaborations among aptamer companies & prominent pharmaceutical and biotechnology firms. The diagnostic segment is projected to grow at the highest CAGR due to the increasing prevalence of chronic diseases and the development of new diagnostic kits to detect cancer and other diseases.

"Pharmaceutical & biotechnology companies are the largest end users of aptamers technology"

Based on end user, the global aptamers market is segmented into pharmaceutical companies & biotechnology companies, academic & government research institutes, contract research organizations, and other end users. In 2020, pharmaceutical & biotechnology companies dominated the market owing to the increasing number of market players offering custom aptamers for use in therapeutics development & rising R&D expenditure. The diagnostic segment will record the highest CAGR during the forecast period due to the development of diagnostic tools for cancer and infectious diseases.

“The DNA-based aptamers segment will continue to dominate the aptamers type market during the forecast period"

Based on type, the aptamers market is segmented into DNA aptamers, XNA aptamers, and RNA aptamers. The DNA-based aptamers segment dominated the market in 2020. The large share of this segment is attributed to their lower production cost and higher stability compared to other nucleic acid-based aptamers and the wide availability of DNA aptamers.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1167

Leading Key Players Analysis:

Some of the key players operating in the aptamers technology market include Aptamer Group (UK), Raptamer Discovery Group (US), SomaLogic Inc., (US), Aptamer Sciences, Inc. (South Korea), Aptagen, LLC (US), Maravai Lifesciences (US), Kaneka Corporation (Japan), NeoVentures Biotechnology Inc. (Canada), Aptus Biotech (Spain), Base Pair Biotechnologies (US), AMSBIO (UK), Novaptech (France), Bio-Techne (US) among others.

Geographical Trends in Detailed:

The global aptamers market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of this market. The largest share of North America is attributed to the availability of funds to develop innovative technologies, the presence of prominent market players, and growing collaborations among companies. The Asia Pacific market is estimated to record the highest CAGR during the forecast period. This is attributed to the rising R&D activities on aptamers, the development of aptamer-based products, and the rising focus on drug discovery and development.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1167

Veterinary Equipment and Disposables Market - In Depth Analysis of Industry Segments, Growth Drivers and Key Players

According to a new market research report “Veterinary Equipment and Disposables Market by Product (Consumables, Anesthesia Machines, Ventilators, Patient Monitoring, Oxygen Masks, Infusion Pumps), Animal (Cats, Dogs, Equines, Bovines), End User (Hospitals, Clinics) – Global Forecast to 2023″, published by MarketsandMarkets™, the global Veterinary Equipment Market is projected to reach USD 2.40 billion by 2023 from USD 1.63 billion in 2018, at a CAGR of 8.0% during the forecast period of 2018 to 2023.

The Veterinary equipment and disposables are used in monitoring, surgeries, and the treatment of diseases in animals. Rising animal health expenditure and growing demand for pet insurance, increasing number of veterinary practitioners in developed regions, and growth in the companion animals market are the primary drivers for the global veterinary equipment market and veterinary disposables market during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=14169630

Growth in the companion animal population;

The adoption of companion animals has grown globally due to the positive health benefits associated with them—reduced cardiac arrhythmias, normalization of blood pressure, decreased anxiety, greater psychological stability, and improved wellbeing. According to the APPA National Pet Owners Survey 2017–2018, the canine population in the US increased from 69.9 million in 2012 to 89.7 million in 2016, while the feline population increased from 74.05 million in 2012 to 94.2 million in 2016. According to the European Pet Food Industry Federation (FEDIAF), the canine population in Germany increased from 5.30 million in 2012 to 8.66 million in 2016, whereas the feline population increased from 8.20 million in 2012 to 13.40 million in 2016.

Emerging markets such as Brazil, China, India, and Mexico are also witnessing growth in animal ownership. According to the India International Pet Trade Fair (IIPTF), the number of pets increased from 11 million in 2014 to 15 million in 2016. Approximately 600,000 pets are adopted every year in India. Such trends are expected to support the growth of the animal health industry, which, in turn, will drive the growth of dependent industries such as veterinary equipment market and veterinary disposables market.

The critical care consumables segment is expected to account for the largest share of the Veterinary Equipment and Disposables Market in 2018. 

On the basis of type, the critical care consumables segment accounted for the largest share of the global Veterinary Equipment and Disposables Market. The large share of consumables can be attributed to the large number of consumables required and consumed in almost every veterinary care process, as opposed to the one-time cost of capital equipment.

The small companion animals will continue to dominate the Veterinary Equipment and Disposables Market during the forecast period.

Based on animal, the small companion animals’ segment will dominate the Veterinary Equipment and Disposables Market in 2023. The large share of this segment can be attributed to the high adoption of companion animals and rising expenditure on animal health.

The veterinary clinics segment is estimated to hold the largest market share of the Veterinary Equipment and Disposables Market in 2023.

Based on end user, veterinary clinics are estimated to hold the largest share of the Veterinary Equipment and Disposables Market in 2023. The large share of this segment can be attributed to the growing number of patient visits along with the increasing number of private clinical practices and increasing practice revenues.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=14169630

North America will dominate the market in 2023. 

North America is estimated to hold the largest share of the Veterinary Equipment and Disposables Market during the forecast period, followed by Europe and the Asia Pacific. Factors such as the increasing number of companion animals, rising companion animal healthcare expenditure, rise in the number of livestock animals in North America (primarily due to the increasing consumption of meat and dairy products), and growth in the pet insurance market are responsible for the region’s large share in the global Veterinary Equipment and Disposables Market.

The prominent players in the Veterinary Equipment and Disposables Market are Mindray Medical International Limited (China), Smiths Group plc (UK), Nonin Medical (US), Digicare Biomedical Technology, Inc. (US), B. Braun Melsungen AG (Germany), Henry Schein (US), Vetland Medical Sales and Services, LLC (US), Hallowell Engineering & Manufacturing Corporation (US), Infiniti Medical, LLC (US), DRE Veterinary (US), and Midmark Corporation (US).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=14169630

Global Back-end Revenue Cycle Management Market Trends and Industry Analysis Report

The research report "Back-End Revenue Cycle Management Market by Product and Services (Claim Processing, Denial Management, Payment Integrity), Delivery Mode (On-Premise, Cloud Based), End-User (Payer, Provider (Inpatient, Outpatient)), and Region - Global Forecast to 2027", is projected to reach USD 12.2 billion by 2027 from USD 8.6 billion in 2019, at a CAGR of 4.4%.

Growing importance of denials management;

To reduce costs and maximize profits, insurance companies are increasingly denying claims as well as coverage to patients being treated for chronic or persistent illnesses. This is putting an extra burden on healthcare providers to manage operating costs, and in turn is supporting the adoption of back-end revenue cycle management solutions (with a growing number of healthcare providers focusing on properly analyzing denied claims and appealing them).

Many healthcare providers across the globe still use manual and paper-oriented approaches to manage denials. This results in errors, delayed follow-ups, and miscommunication between healthcare providers and insurance companies. The use of back-end revenue cycle management solutions over manual and paper-oriented approaches can not only help healthcare providers overcome these issues but also help them save significant costs. As a result, the demand for back-end revenue cycle management solutions is expected to increase among end users during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=204439794

Leading Key Players and Analysis:

Athenahealth (US), Cerner Corporation (US), Allscripts Healthcare Solutions, Inc. (US), eClinicalWorks (US), Optum, Inc. (US), McKesson Corporation (US), Conifer Health Solutions (US), GeBBs Healthcare Solutions (US), The SSI Group (US), GE Healthcare (US), nThrive (US), DST Systems (US), Cognizant Technology Solutions (US), and Quest Diagnostics (US) are the key players in the Back-End RCM Market.

Cerner has a strong foothold in the back-end revenue cycle management market. The company caters to the healthcare technology and financial management needs of its global customers. Cerner focuses on research and development activities, deploying products, and acquisitions to enhance its market presence. For instance, in the past three years, the company deployed more than 15 back-end revenue cycle management solutions across various hospitals, care centers, and medical centers. The acquisition of Siemens Health Services in January 2015 further strengthened its back-end revenue cycle management portfolio.

Geographical Analysis in Detailed?

The back-end revenue cycle management market is divided into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share in 2018 owing to factors such as growing HCIT investments in the region and the presence of regulatory mandates. North America is followed by Europe and Asia. The market in Asia is relatively nascent; however, it is projected to be the fastest-growing market during the forecast period.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=204439794

Industry Segmentation:

The Services segment to dominate the back-end revenue cycle management market.

By product & service, segmented into software and services. The services segment is expected to account for the largest share of the Back-End RCM Market in 2018. The large share of this segment can be attributed to the recurring nature of services such as training and development, installation, software upgrades, consulting, and maintenance. However, due to the need for periodic software upgrades, the software segment is expected to witness the highest growth during the forecast period.

The cloud-based systems to register the highest CAGR during the forecast period

On the basis of delivery mode, segmented into on-premise and cloud-based systems. The cloud-based segment is expected to register the highest CAGR of the back-end revenue cycle management market during the forecast period. Growth in this segment can be attributed to the comparatively lower capital expenses and operational costs incurred in this model, alongside its scalability, flexibility, and affordability.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=204439794